The genetic basis of hypertriglyceridemia

GD Carrasquilla, MR Christiansen… - Current atherosclerosis …, 2021 - Springer
Abstract Purpose of Review Hypertriglyceridemia is a common dyslipidemia associated with
an increased risk of cardiovascular disease and pancreatitis. Severe hypertriglyceridemia …

Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid

MJ Chapman, JL Zamorano, KG Parhofer - Pharmacology & therapeutics, 2022 - Elsevier
Atherosclerotic cardiovascular disease (ASCVD) and its atherothrombotic complications
impose a substantial disease burden in Europe, representing a cost of€ 210 billion per year …

How to handle elevated triglycerides: life after prominent

A Pirillo, AL Catapano - Current Atherosclerosis Reports, 2023 - Springer
Abstract Purpose of Review Hypertriglyceridaemia (HTG) is a common condition
characterised by elevated levels of plasma triglycerides (TG), which are transported in the …

Analysis of the mechanism of action of quercetin in the treatment of hyperlipidemia based on metabolomics and intestinal flora

T Wang, L Liu, J Deng, Y Jiang, X Yan, W Liu - Food & function, 2023 - pubs.rsc.org
Hyperlipidemia (HLP) is one of the main factors leading to cardiovascular diseases.
Quercetin (QUE) is a naturally occurring polyhydroxy flavonoid compound that has a wide …

Prevalence of US adults with triglycerides≥ 150 mg/dl: NHANES 2007–2014

W Fan, S Philip, C Granowitz, PP Toth, ND Wong - Cardiology and therapy, 2020 - Springer
Introduction Hypertriglyceridemia is associated with increased atherosclerotic
cardiovascular disease (ASCVD) event risk, which persists even in statin-treated patients …

Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment

WS Weintraub, DL Bhatt, Z Zhang, S Dolman… - JAMA Network …, 2022 - jamanetwork.com
Importance The Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial
(REDUCE-IT) demonstrated the efficacy of icosapent ethyl (IPE) for high-risk patients with …

Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction

WE Boden, S Baum, PP Toth, S Fazio, DL Bhatt - Future cardiology, 2021 - Taylor & Francis
Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk. The
Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) …

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

M Pareek, RP Mason, DL Bhatt - Expert Opinion on Drug Safety, 2022 - Taylor & Francis
Introduction In patients at high cardiovascular risk, the rate of events remains elevated
despite traditional, evidence-based lipid-lowering therapy. Residual hypertriglyceridemia is …

Icosapent ethyl for primary versus secondary prevention of major adverse cardiovascular events in hypertriglyceridemia: Value for money analysis

R Arbel, E Aboalhasan, A Hammerman… - The American Journal of …, 2021 - Elsevier
Background Icosapent ethyl (IPE) is approved for the prevention of major adverse
cardiovascular events (MACE) in patients with hypertriglyceridemia. However, due to budget …

Hypertriglyceridemia and Other Plasma Lipid Profile Abnormalities among People Living with Diabetes Mellitus in Ethiopia: A Systematic Review and Meta‐Analysis

B Dagnew, Y Yeshaw, D Geremew… - BioMed Research …, 2021 - Wiley Online Library
Background. Dyslipidemia is one of the leading causes of cardiovascular complications in
diabetes mellitus (DM) patients. Though it is a major public health problem in Ethiopia, there …